Review
Cardiac & Cardiovascular Systems
Yinghui Wang, Yonggang Wang, Xiaorong Han, Jian Sun, Cheng Li, Binay Kumar Adhikari, Jin Zhang, Xiao Miao, Zhaoyang Chen
Summary: Cardiovascular disease (CVD) and cancer are leading causes of death worldwide. The adverse effects of anti-tumor therapy, particularly on the cardiovascular system, have gained significant attention. Incidence of cardiovascular events is higher than tumor recurrence rate, and CVD and malignant tumors share common risk factors. Clinicians should understand this relationship, provide primary and secondary prevention strategies, and follow proper treatment methods.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Katarina Yaros, Benay Eksi, Alvin Chandra, Kartik Agusala, Lorenz H. Lehmann, Vlad G. Zaha
Summary: Cardiovascular imaging plays an important role in the care of cancer patients, as they face increased risks of cardiovascular complications. Currently established imaging modalities are evolving towards increased specificity, while new modalities are emerging to target earlier stages of cardiovascular disease. Choosing suitable imaging modalities for individual patients is crucial for successful risk stratification. Future imaging tools have the potential to provide insights into the molecular pathology of cardiovascular complications associated with cancer and oncological therapies.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Dong-Woo Kang, Rebekah L. Wilson, Cami N. Christopher, Amber J. Normann, Oscar Barnes, Jordan D. Lesansee, Gyuhwan Choi, Christina M. Dieli-Conwright
Summary: Anthracycline-induced cardiotoxicity is a serious clinical problem that needs to be addressed. Exercise therapy, as a non-pharmacological intervention, has potential benefits in preventing and managing cardiotoxicity caused by anthracyclines. However, the underlying mechanisms of exercise and its implementation in clinical settings to improve long-term cardiovascular outcomes require further research.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Medicine, Research & Experimental
Carlos D. Vera, Agustin Rodriguez Lopez, Alex S. Ewaneewane, Kasey Lewis, Sophia Parmisano, Gema Mondejar-Parreno, Chandan Upadhyaya, Mckay Mullen
Summary: Cancer and cardiovascular diseases are the top two causes of death in the United States. While novel therapies have slowed down cancer mortality rate, there has been an increase in cardiac failures due to the toxicity of cancer treatments. Understanding the mechanisms behind this relationship is crucial in properly treating patients at risk of developing cardiac failure. Currently, early-stage biomarkers of inflammation and angiogenesis are used to detect cardiotoxicity before it becomes irreversible, with the aim of minimizing the adverse effects of cancer therapies. In the field of cardio-oncology, there is growing focus on gender and racial disparities in cardiotoxicity and their impact on disease outcomes, although data on variations in cardiotoxicity across diverse populations is limited.
Review
Oncology
Mengjia Chen, Jianing Xue, Maoling Wang, Junyao Yang, Ting Chen
Summary: The potential coexistence of cardiovascular disease and cancer is more likely in long-term survivors due to advancements in cancer therapy. Cardiotoxicity is a well-known and concerning adverse effect of cancer treatments, which can lead to the discontinuation of life-saving anticancer treatments and negatively impact patient survival. Different anticancer treatments have varying effects on the cardiovascular system, and the incidence of cardiovascular events also varies among different tumor protocols. Comprehensive cardiovascular risk assessment and clinical monitoring should be considered for cancer treatments, with emphasis on baseline cardiovascular evaluation risk before initiating therapy. Additionally, cardio-oncology services are needed to identify and reduce cardiovascular side effects, as well as minimize long-term cardiotoxic effects.
Review
Medicine, General & Internal
Shawn Simek, Brian Lue, Anjali Rao, Goutham Ravipati, Srilakshmi Vallabhaneni, Kathleen Zhang, Vlad G. Zaha, Alvin Chandra
Summary: Gender differences exist in the medical field, including cardio-oncology. Gender may influence cancer susceptibility, cardiotoxicities, healthcare, and cancer treatments.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Alessandra Cuomo, Valentina Mercurio, Gilda Varricchi, Maria Rosaria Galdiero, Francesca Wanda Rossi, Antonio Carannante, Grazia Arpino, Luigi Formisano, Roberto Bianco, Chiara Carlomagno, Carmine De Angelis, Mario Giuliano, Elide Matano, Marco Picardi, Domenico Salvatore, Ferdinando De Vita, Erika Martinelli, Carminia Maria Della Corte, Floriana Morgillo, Michele Orditura, Stefania Napolitano, Teresa Troiani, Carlo G. Tocchetti
Summary: A large Cardio-Oncology unit in Southern Italy has described the impact on 231 consecutive patients referred to their unit, categorizing patients into three types based on their chemotherapeutic statuses. Results showed that patients already being treated with oncological treatments (Type 2) had the highest incidence of cardiovascular events, withdrawals from oncological treatments, and worst 48-month survival compared to other types.
Review
Oncology
Jakub Bychowski, Wojciech Sobiczewski
Summary: Cancer and cardiac diseases are the leading causes of death in developed countries. Due to advancements in detection and treatment, more cancer patients are surviving and living longer. However, there is an increasing risk of cardiovascular complications from cancer therapies, such as heart dysfunction and premature heart disease. Cardio-oncology is a new field that focuses on screening, diagnosis, and prevention of these adverse effects. This review discusses the most relevant studies on cardiac effects of oncological therapy and methods for prevention.
Review
Cardiac & Cardiovascular Systems
Flavio D'Ascenzi, Francesca Anselmi, Caterina Fiorentini, Roberta Mannucci, Marco Bonifazi, Sergio Mondillo
Summary: This review focuses on investigating the origin, prevention, and reversal strategies of cardiac damage, and explores the beneficial effects of physical exercise on cancer patients. It suggests personalized exercise prescriptions and emphasizes the importance of cardiac evaluation in prescribing exercise for these patients.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Giacomo Tini, Alessandra Cuomo, Allegra Battistoni, Matteo Sarocchi, Valentina Mercurio, Pietro Ameri, Massimo Volpe, Italo Porto, Carlo Gabriele Tocchetti, Paolo Spallarossa
Summary: This study investigated the CV risk assessment, prescriptions of cardioactive drugs, and occurrence of CV events in breast cancer patients. The study found that patients with medium-to-high CV risk were more likely to receive cardioactive therapies, but the risk categories were not associated with LVD occurrence.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Michal Laufer-Perl, Orly Arias, Svetlana Sirota Dorfman, Guy Baruch, Ehud Rothschild, Gil Beer, Shira Peleg Hasson, Yaron Arbel, Zach Rozenbaum, Yan Topilsky, Livia Kapusta
Summary: This study aimed to evaluate changes in left atrial strain (LAS) during Anthracycline (ANT) therapy in female breast cancer patients and to assess the correlation between LAS and routine echocardiographic diastolic parameters. The results showed significant reductions in LASr and LASc are frequent during ANT therapy, with significant correlation to routine echocardiographic diastolic parameters, indicating a potential role in early detection of cardiotoxicity.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Jacqueline T. Vuong, Ashley F. Stein-Merlob, Richard K. Cheng, Eric H. Yang
Summary: Anthracyclines are important in the treatment of various cancers, but can have significant implications on cardiovascular health. As the number of cancer survivors increases, it becomes crucial to detect and treat anthracycline-induced cardiotoxicity. Current treatment methods are based on conventional heart failure treatment, but there is a need for specific therapies for anthracycline-induced cardiotoxicity.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Carlos Galan-Arriola, Jean Paul Vilchez-Tschischke, Manuel Lobo, Gonzalo J. Lopez, Antonio De Molina-Iracheta, Claudia Perez-Martinez, Rocio Villena-Gutierrez, Alvaro Macias, Ivan A. Diaz-Rengifo, Eduardo Oliver, Valentin Fuster, Javier Sanchez-Gonzalez, Borja Ibanez
Summary: The aim of this study was to investigate the changes in coronary microcirculation status during and after repeated anthracycline treatment. The results showed that anthracycline treatment is associated with progressive and irreversible damage to the microcirculation. The damage to the microcirculation persists even in low cumulative dose regimes and may explain the increased incidence of cardiovascular events in cancer survivors who received anthracyclines without cardiac contractile defects.
CARDIOVASCULAR RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Zehua Liang, Yuquan He, Xin Hu
Summary: Chemotherapy-induced cardiovascular toxicity has become a major concern in cancer therapy. Traditional Chinese medicine formulations and the emerging field of reverse cardio-oncology provide promising approaches for prevention and treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cardiac & Cardiovascular Systems
Christopher E. D. Saunderson, Sven Plein, Charlotte H. Manisty
Summary: Advances in cancer therapy have led to longer cancer-free survival times, but also increased the risk of cardiovascular disease. The emergence of cardio-oncology services has provided important support for early diagnosis and prevention of cardiac toxicity. Cardiovascular imaging and CMR are increasingly important in the field of cardio-oncology for early detection and understanding of cancer treatment-related heart toxicity.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
(2021)
Article
Multidisciplinary Sciences
Marianne K. O. Grant, Ibrahim Y. Abdelgawad, Christine A. Lewis, Davis Seelig, Beshay N. Zordoky
Letter
Oncology
Anne Blaes, Suma Konety, Beshay Zordoky
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Biochemistry & Molecular Biology
Zaid H. Maayah, Abrar S. Alam, Shingo Takahara, Shubham Soni, Mourad Ferdaoussi, Nobutoshi Matsumura, Beshay N. Zordoky, David D. Eisenstat, Jason R. B. Dyck
Summary: DOX is an effective anticancer agent but can cause cardiotoxic effects. Co-treatment with RES can attenuate cardiac injury by reducing systemic inflammation.
Review
Pharmacology & Pharmacy
Ibrahim Y. Abdelgawad, Karim T. Sadak, Diana W. Lone, Mohamed S. Dabour, Laura J. Niedernhofer, Beshay N. Zordoky
Summary: Cancer treatment can accelerate aging and increase the risk of cardiovascular complications. While there are approaches to mitigate therapy-induced senescence, strategies to prevent and treat cardiovascular senescence have not yet been translated to clinical practice.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Ibrahim Y. Abdelgawad, Marianne K. O. Grant, Flavia E. Popescu, David A. Largaespada, Beshay N. Zordoky
Summary: DOX is widely used in pediatric oncology and induces inflammatory response; the study found that DOX treatment suppressed tumor growth but caused cardiac atrophy in both tumor-free and tumor-bearing mice; EL4 lymphoma cells elicited inflammatory response in heart, liver, and kidney.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Veterinary Sciences
Kristine Walters, Alessia Stornetta, Foster Jacobs, Peter W. Villalta, Maria Razzoli, Marianne Grant, Beshay Zordoky, Alessandro Bartolomucci, Antonella Borgatti, Silvia Balbo
Summary: This study introduced a novel mass spectrometry approach for identifying doxorubicin-DNA adducts, aiming to personalize chemotherapy protocols for veterinary cancer patients. It also demonstrated the detection capability of doxorubicin and its related molecules in vitro and in vivo, laying the foundation for future biomarker development in veterinary oncology.
BMC VETERINARY RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Ibrahim Y. Abdelgawad, Kevin Agostinucci, Beshay N. Zordoky
Summary: Therapy-induced senescence is a fundamental mechanism contributing to adverse health complications in cancer survivors. This mini-review focuses on the mechanisms of endothelial cell senescence and discusses novel senotherapeutic approaches.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2022)
Article
Cardiac & Cardiovascular Systems
Kevin Agostinucci, Marianne K. O. Grant, Davis Seelig, Dogacan Yucel, Jop van Berlo, Alessandro Bartolomucci, Jason R. B. Dyck, Beshay N. Zordoky
Summary: This study aims to investigate whether pre-exposure to doxorubicin during adolescence would make the heart more susceptible to non-hypertensive pathologic stimuli. The results show that doxorubicin-induced latent cardiotoxicity enhances the cardiac response to hypertensive stimuli and is associated with worsened cardiac function and increased fibrosis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cell Biology
Ibrahim Y. Abdelgawad, Kevin Agostinucci, Somia G. Ismail, Marianne K. O. Grant, Beshay N. Zordoky
Summary: The research found that DOX-induced senescence demonstrates similar phenotypes between EA.hy926 cells and HUVECs, but they respond differently to ABT-263.
Article
Multidisciplinary Sciences
Anne H. Blaes, Chandini Nair, Susan Everson-Rose, Patricia Jewett, Jack Wolf, Beshay Zordoky
Summary: The use of aromatase inhibitors (AIs) in breast cancer survivors is associated with higher cardiovascular events and lower endothelial function. Psychosocial stress is associated with increased levels of inflammatory markers and decreased endothelial function in healthy individuals. This study investigated the associations between psychosocial measures and markers of inflammation, aging, and endothelial function in breast cancer survivors on AIs. Positive correlations were observed between psychosocial measures and inflammatory markers, but no associations were found with endothelial function or aging biomarkers. These findings suggest that psychosocial stress may contribute to inflammation in breast cancer survivors on AIs, but further research is needed to understand the relationships between inflammation, aging, and endothelial function in this population.
SCIENTIFIC REPORTS
(2023)
Article
Chemistry, Medicinal
Kevin Agostinucci, Marianne K. O. Grant, Wongel Melaku, Chandini Nair, Beshay N. N. Zordoky
Summary: Sex is an important risk factor in the development of doxorubicin-induced cardiotoxicity. The study found sexual differences in the heart's response to hypertrophic stimuli in doxorubicin-exposed mice. Pre-exposure to doxorubicin caused male-specific cardiac atrophy that persisted after isoproterenol treatment, which could not be prevented by gonadectomy. However, there were no sex differences in the expression of markers of pathological hypertrophy, fibrosis, or inflammation.
Article
Geriatrics & Gerontology
Ibrahim Y. Abdelgawad, Kevin Agostinucci, Bushra Sadaf, Marianne K. O. Grant, Beshay N. Zordoky
Summary: This study demonstrates that metformin can mitigate DOX-induced endothelial cell senescence phenotype and ameliorate the hyper-inflammatory response to LPS. These findings suggest that metformin may protect against DOX-induced vascular aging and endothelial dysfunction and ameliorate infection-induced hyper-inflammation in DOX-treated cancer survivors.
FRONTIERS IN AGING
(2023)
Article
Behavioral Sciences
Marianne K. O. Grant, Maria Razzoli, Ibrahim Y. Abdelgawad, Rachel Mansk, Davis Seelig, Alessandro Bartolomucci, Beshay N. Zordoky
Summary: This study established a mouse model of juvenile DOX-induced cardiotoxicity predisposing to adult-onset stress-induced adverse cardiac remodeling. Results showed that juvenile exposure to DOX followed by adult-onset CSS caused cardiac fibrosis and inflammation, along with upregulated gene expression of multiple inflammatory and fibrotic markers.
STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS
(2022)
